title: Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
abstract: The aim of this study was to determine the efficacy of sagopilone (ZK-EPO), a novel epothilone, compared with other anticancer agents in orthotopic models of human primary and secondary brain tumors. Autoradiography and pharmacokinetic analyses were performed on rats and mice to determine passage across the blood-brain barrier and organ distribution of sagopilone. Mice bearing intracerebral human tumors (U373 or U87 glioblastoma, MDA-MB-435 melanoma, or patient-derived non-small-cell lung cancer [NSCLC]) were treated with sagopilone 5-10 mg/kg, paclitaxel 8-12.5 mg/kg (or temozolomide, 100 mg/kg) or control (vehicle only). Tumor volume was measured to assess antitumor activity. Sagopilone crossed the blood-brain barrier in both rat and mouse models, leading to therapeutically relevant concentrations in the brain with a long half-life. Sagopilone exhibited significant antitumor activity in both the U373 and U87 models of human glioblastoma, while paclitaxel showed a limited effect in the U373 model. Sagopilone significantly inhibited the growth of tumors from CNS metastasis models (MDA-MB-435 melanoma and patient-derived Lu7187 and Lu7466 NSCLC) implanted in the brains of nude mice, in contrast to paclitaxel or temozolomide. Sagopilone has free access to the brain. Sagopilone demonstrated significant antitumor activity in orthotopic models of both glioblastoma and CNS metastases compared with paclitaxel or temozolomide, underlining the value of further research evaluating sagopilone in the treatment of brain tumors. Sagopilone is currently being investigated in a broad phase II clinical trial program, including patients with glioblastoma, NSCLC, breast cancer, and melanoma.
authors.affiliation: Bayer Schering Pharma AG, TRG Oncology, Berlin, Germany. jens.hoffmann@bayerhealthcare.com
authors.forename: Jens
authors.initials: J
authors.lastname: Hoffmann
authors.forename: Iduna
authors.initials: I
authors.lastname: Fichtner
authors.forename: Margit
authors.initials: M
authors.lastname: Lemm
authors.forename: Philip
authors.initials: P
authors.lastname: Lienau
authors.forename: Holger
authors.initials: H
authors.lastname: Hess-Stumpp
authors.forename: Andrea
authors.initials: A
authors.lastname: Rotgeri
authors.forename: Birte
authors.initials: B
authors.lastname: Hofmann
authors.forename: Ulrich
authors.initials: U
authors.lastname: Klar
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000627:therapeutic use; D052160:Benzothiazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D034261:Epothilones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate; D000077204:Temozolomide; D023041:Xenograft Model Antitumor Assays
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D052160:Benzothiazoles; D034261:Epothilones; D003606:Dacarbazine; C530494:sagopilone; D017239:Paclitaxel; D000077204:Temozolomide
references.citation: J Nucl Med. 2005 Nov;46(11):1866-71
references.pmid: 16269601
references.citation: J Neurooncol. 2003 Feb;61(3):203-7
references.pmid: 12675312
references.citation: Gynecol Oncol. 1994 Dec;55(3 Pt 1):456-8
references.pmid: 7835788
references.citation: Curr Probl Surg. 2004 Aug;41(8):665-741
references.pmid: 15354117
references.citation: Cancer. 1995 Jul 15;76(2):232-6
references.pmid: 8625097
references.citation: Int J Gynecol Cancer. 2006 May-Jun;16(3):994-9
references.pmid: 16803475
references.citation: Eur J Cancer. 2003 Jun;39(9):1271-6
references.pmid: 12763216
references.citation: Cancer Res. 2008 Jul 1;68(13):5301-8
references.pmid: 18593931
references.citation: Exp Biol Med (Maywood). 2005 Feb;230(2):118-27
references.pmid: 15673560
references.citation: Nat Clin Pract Neurol. 2006 Sep;2(9):494-503; quiz 1 p following 516
references.pmid: 16932614
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5770-6
references.pmid: 17020983
references.citation: Neurol Clin. 2003 Feb;21(1):107-40, viii
references.pmid: 12690647
references.citation: Cancer. 2002 Aug 1;95(3):605-12
references.pmid: 12209754
references.citation: Ann Oncol. 2001 Mar;12(3):353-6
references.pmid: 11332148
references.citation: Ann Oncol. 2006 Jun;17(6):952-6
references.pmid: 16565212
references.citation: J Anat. 2002 Jun;200(6):629-38
references.pmid: 12162730
references.citation: Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8
references.pmid: 17006870
references.citation: J Neurooncol. 2003 Nov;65(2):99-106
references.pmid: 14686728
references.citation: Chin Med J (Engl). 2007 Mar 20;120(6):458-62
references.pmid: 17439736
references.citation: Cancer. 2002 May 15;94(10):2698-705
references.pmid: 12173339
references.citation: Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1186-95
references.pmid: 12654426
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Am J Pathol. 2005 Oct;167(4):913-20
references.pmid: 16192626
references.citation: J Neurosurg. 1998 Jan;88(1):11-20
references.pmid: 9420067
references.citation: J Neurooncol. 2005 Oct;75(1):5-14
references.pmid: 16215811
references.citation: J Clin Oncol. 1999 Sep;17(9):2762-71
references.pmid: 10561351
references.citation: Br J Cancer. 2004 Aug 16;91(4):639-43
references.pmid: 15266327
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2865-72
references.pmid: 15254054
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8
references.pmid: 16203787